ABUS NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Arbutus Biopharma Corp · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 4.34 USD
-0.9% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is -0.5% below the Trend Line and sits at 50.9% of its 52-week range. The latest completed week returned -0.9%, after a -10.9% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 53/100 conviction, while the latest news-sentiment score is 56/100. Near-term considerations: volume confirmation is below normal; earnings are due in 3d.

Setup score 33 out of 100
Latest Close 4.34 USD 31 Jul 2026
1W Return -0.9% latest completed week
4W Return -10.9% short-term follow-through
12W Return 0.0% quarterly tape
Trend Breadth 53.8% 28 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • The trend backdrop is active with a 5-week active streak.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • 4 reversal markers appear in the recent smart-money tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -0.9% Latest completed week; four-week move -10.9%. Indicator stack 47/53 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 53/100 conviction; expected move 17.3%. News sentiment 56/100 59 relevant articles in the latest sentiment read. Event risk 3d Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is -0.5% below the Trend Line and sits at 50.9% of its 52-week range. The latest completed week returned -0.9%, after a -10.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.5012-week average 0.36

12-week confirmation

Trend active5/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure8/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership1/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.50Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers44 reversal markers

No recent accumulation markers. 4 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -10.9% over four weeks, 0.0% over 12 weeks, and 32.7% over one year. The current trend has remained active for 5 consecutive weeks.

Performance by holding period

1W-0.9%
4W-10.9%
12W0.0%
26W5.1%
52W32.7%
Active trend streak5 weeks
Active weeks in one year28
Trend breadth53.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.34Latest activity-pressure read.
Pressure change-38.7%Four-week change in activity pressure.
Leadership-8.26Latest relative-leadership reading.
RS change-4196.3%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 91% Model confidence 87%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength92/100Blend of value, momentum, and quality. Underlying universe rank 9; rank 1 is best.
Value77/100Relative valuation strength. Underlying universe rank 24; rank 1 is best.
Quality79/100Profitability and accounting quality. Underlying universe rank 22; rank 1 is best.
Momentum81/100Medium-term price momentum. Underlying universe rank 20; rank 1 is best.
Growth37/100Revenue and earnings growth. Underlying universe rank 64; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework96/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
5.4x
Price divided by trailing earnings.
Price / sales
4.5x
Market value relative to trailing revenue.
EV / EBITDA
5.3x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-3.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
100.0%
Gross profit retained from each unit of revenue.
Operating margin
84.0%
Operating profit retained from revenue.
Free-cash-flow margin
-13.7%
Free cash flow generated from revenue.
Return on invested capital
50.2%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

ABUS shows volatility options pressure with a 53/100 conviction score, put-call volume ratio of 0.16, expected move of 17.3%, and Sharemaestro trend signal active.

Conviction53/100
Expected move17.3%
Put/call volume0.16
Pressure79
Speculation40
Volatility86
Trend agreement8
Open options detail
Insider activity2 / 0

2 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment56/100

Weighted news tone is neutral across 59 relevant articles.

19 positive · 36 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings3dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move17.3%Nearest-chain priced movement where available.
52-week drawdown-19.3%Distance below the 52-week high.
13-week volatility4.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+13.7%Week of 17 Apr.
Worst week-11.0%Week of 24 Apr.
Latest week-0.9%Week of 31 Jul.

Shape of recent returns

Strong gains7
Modest gains7
Flat weeks0
Modest losses6
Sharp losses6
Recent vol4.0%13-week weekly-return volatility.
Base vol5.7%52-week weekly-return volatility.
Up/down split28/23Count of positive and negative weeks in the 52-week window.
Average skew4.9% / -4.3%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape35/100

Trend, activity pressure, participation, and risk combine to a 35/100 tape read.

 Indicator analysis36/100

Latest 12-week confirmation: trend 5/12, activity pressure 8/12, relative leadership 1/12.

Activity pressure 0.50; 4 reversal markers Factors82/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 54; Small Cap Core rank 40 SVQF96/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 27.5 of 726 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options38/100

ABUS shows volatility options pressure with a 53/100 conviction score, put-call volume ratio of 0.16, expected move of 17.3%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 17.3% Sentiment56/100

Weighted news tone is neutral across 59 relevant articles.

Arbutus Biopharma Corp (ABUS) Risk Assessment: Volatility, Financial Risk & Investment Risk Insiders2 / 0

2 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings3d

Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20264.34 USD-0.9%4.36 USD3.46 USD0.34-8.265.6MOn
24 Jul 20264.38 USD-3.9%4.38 USD3.45 USD0.76-6.817.8MOn
17 Jul 20264.56 USD-5.0%4.39 USD3.44 USD1.11-4.349.0MOn
10 Jul 20264.80 USD-1.4%4.39 USD3.42 USD1.07-3.2316.9MOn
3 Jul 20264.87 USD6.3%4.38 USD3.40 USD0.550.2011.5MOn
26 Jun 20264.58 USD0.7%4.37 USD3.39 USD0.01-4.6921.3MOff
19 Jun 20264.55 USD6.8%4.36 USD3.37 USD-0.15-9.389.3MOff
12 Jun 20264.26 USD0.2%4.35 USD3.36 USD-0.28-12.996.7MOff
5 Jun 20264.25 USD-6.8%4.36 USD3.35 USD-0.15-11.396.2MOff
29 May 20264.56 USD4.8%4.37 USD3.34 USD0.02-9.359.4MOff
22 May 20264.35 USD2.6%4.38 USD3.32 USD-0.05-11.117.4MOff
15 May 20264.24 USD-2.3%4.38 USD3.31 USD0.01-12.375.7MOff
8 May 20264.34 USD0.5%4.38 USD3.30 USD0.15-10.584.1MOff
1 May 20264.32 USD2.9%4.38 USD3.29 USD0.01-6.249.3MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.